Efficacy of PRF and Xenograft in Treating Mandibular Molar Furcation Involvements

Inclusion Criteria: * Patients over 18 years old * Patients diagnosed with periodontitis who have completed non-surgical treatment: scaling and root planing * Patients attending a follow-up visit at least 5 weeks after non-surgical treatment, demonstrating compliance and good oral hygiene cooperation * Presence of a mandibular molar with a Degree II furcation involvement according to Hamp (1975), presenting a residual periodontal pocket at the buccal site (PPD ≥ 5mm) after non-surgical treatment, and showing radiolucency in the furcation area on CBCT imaging * Plaque Index (PlI) \< 1 following non-surgical treatment * Width of keratinized gingiva ≥ 2mm * Teeth with furcation defects where gingival recession does not extend apically beyond the buccal furcation fornix (no supragingival furcation exposure) * Teeth without occlusal trauma, pulpal or periapical pathologies, and no combined periodontic-endodontic lesions * Degree II furcation involvement according to Hamp (1975) and Subclass A or B according to Tarnow and Fletcher (1984) * The defect is located apical to the interproximal alveolar bone crest on CBCT imaging Exclusion Criteria: * Patients with systemic diseases affecting periodontal treatment outcomes, such as: diabetes mellitus, heart disease requiring anticoagulant therapy, blood disorders, immunodeficiency, etc * Pregnant or lactating patients * Patients who have used antibiotics or any other medications affecting periodontal treatment outcomes within the last 6 months * Patients who smoke tobacco. * Patients who have used aspirin or medications affecting blood coagulation within 2 weeks prior to the blood collection for PRF preparation * Patients with a history of allergy to local anesthetics * Defects associated with grade II tooth mobility that has not been splinted, or grade III tooth mobility according to Miller (2014)